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Case report

Life Threatening haemoptysis in primary lung cancer-signet ring
cell carcinoma
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Primary signet ring cell carcinoma of the lung is a rare non-small cell carcinoma of the lung with extremely
aggressive features and poor prognosis. The diagnosis mainly required tissue biopsy with immunohistochemical
analysis and gene mutation studies. We describe a unique case of primary signet ring cell carcinoma of the lung
presenting with life threatening haemoptysis along with literature review of prognosis and management of this
rare clinical entity.

1. Case description
A 57-year old male with pertinent past medical history of diabetes
and hypertension presented to the emergency department with active
haemoptysis. Patient had relevant social history of 44 pack years of
smoking. He initially developed mild haemoptysis hence was evaluated
by his primary care physician one month ago. The initial chest X-ray
(Fig. 1) showed right sided lung mass suspicious of malignancy
prompting the patient to undergo Positron Emission Tomographic (PET)
scan which re-demonstrated right sided lung mass along with diffuse
mediastinal & cervical lymphadenopathy and adrenal gland metastasis
(Fig. 2).
The patient was scheduled for biopsy of the mass for identification of
the malignancy however, the haemoptysis worsened to the point that he
started actively throwing up blood clots from his mouth prompting his
visit to the emergency department. The patient remained stable hemo
dynamically despite having active haemoptysis of >150 mL (ml) in 24
hours. He was emergently evaluated by the pulmonary and critical team
and underwent bronchoscopy with argon plasma coagulation (APC)
cauterization to control the bleeding and biopsies were taken. As part of
staging of malignancy, he also underwent magnetic resonance imaging
(MRI) of the brain which showed a punctuate right cerebellar lesion with
mild edema consistent for metastasis (Fig. 3).
The initial pathology of the lung mass suggested signet cell features
so the patient underwent esophagogastroduodenoscopy (EGD) to
exclude gastric cancer as the primary malignancy. The EGD demon
strated normal mucosa with mild non-erosive gastritis, thereby estab
lishing the diagnosis of primary signet cell adenocarcinoma of the lung.

The immunohistochemical staining showed neoplastic cells positive for
CK7, TTF-1 and mucicarmine while CK20, p63, CK 5&6 were negative.
The tumor proportion score (TPS) for PD-L1 protein expression was 0%.
The patient was hemodynamically stabilized with resolution of
haemoptysis after bronchoscopy and cauterization. As the lesion in the
brain was very small and patient remained asymptomatic, radiation
oncology recommended no further intervention at this time with short
tapered course of high dose steroids. Next generation sequencing (NGS)
studies were sent for further characterization of the adenocarcinoma. A
total of seven disease relevant genes with no alterations resulted, which
included ALK, BRAF, EGFR, ERBB2, MET, RET and ROS1. No micro
satellite instability was noted. As no driver mutations were noted in the
NGS, patient was decided to be initiated on platinum based (carbopla
tin)and paclitaxel intravenous chemotherapy every week for three
weeks with one week off between each cycle. As biomarker K-ras G12 C
mutation on genomic profiling was noted immune check point inhibitor
pembrolizumab has been added to the therapy. The patient is currently
being followed closely with haematology oncology for clinical response
to chemotherapy.
2. Discussion
Primary signet ring cell carcinoma (SRCC) is a rare subtype of lung
adenocarcinoma with often poorly differentiated cells. More commonly
SRCC in the lung is seen as a metastatic lesion with primary cancer
arising from different organs such as stomach, bladder, prostate and
breast [1]. According to one literature review, the rarity of SRCC can be
estimated as approximately 0.5% of the all the adenocarcinomas of the
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Fig. 1. Chest X-ray.

lung [2]. The median age of individuals affected with SRCC was noted to
be 64 years, slightly lower as compared to the age of overall population
affected with lung adenocarcinomas (median age 67). The study also
suggested that approximately 49.2% of the SRCC patients were already
in Stage IV at the time of presentation as compared to 36.8 %in overall
lung adenocarcinoma and decreased overall survival (6 months vs 10
months, respectively) suggesting highly aggressive nature. The primary
site of malignancy in signet cell carcinoma has been noted as an inde
pendent prognostic factor with 5-year survival rate of primary SRCC of
the lung noted to be approximately 11% [3].
The patients may present with subtle and non-specific symptoms of
weight loss, cough, chest pain, difficulty in breathing and haemoptysis.
Life threatening haemoptysis as described in our clinical scenario was a
unique presentation of the SRCC. Like all cancers, the definitive diag
nosis of primary lung SRCC is made by tissue biopsy with histopatho
logical examination and immunohistochemical staining. On histology,
the cells demonstrate clear cytoplasm with peripherally displaced
hyperchromatic nuclei with distinct cell borders [4]. The immunohis
tochemical staining profile for primary lung SRCC variably features
positive markers such as TTF-1, CK-7, p63 and mucicarmine with
negative for CK20, CK 5/6, chromogranin, synaptophysin and vimentin
[5,6].
In order determine the lung being the primary origin for SRCC, it is
also important to exclude the possibility of metastatic with primary
origin for SRCC elsewhere such as stomach, breast and prostate. Our
patient failed to demonstrate any active malignancy of initial PET scan
in other organ systems and underwent EGD with biopsies to rule out
gastric origin of cancer. This conclusion is further supported with
immunohistochemistry (positive CK7 and TTF-1 and negative CK20)
which suggests primarily a lung cancer [7]. Fluorescence in situ

Fig. 3. MRI of the brain.

hybridization (FISH) in primary lung SRCC may often demonstrate ALK
gene translocation with EML4-ALK fusion and absence of EGFR and
KRAS mutations. These mutations may have a therapeutic significance
as tumors with EML4-ALK translocation have shown to some response to
ALK inhibitor Crizotinib and K-ras with immune check point inhibitors
like Pembrolizumab [8–10]. Utilization of next generation sequence to
check for driver mutations specially in advanced non-small cell lung
carcinoma has increasingly become a standard part of diagnostic
work-up. It enables in checking for various driver mutations including
EGFR, ALK, ROS-1 and provides useful information in choosing
chemotherapy as well as median survival age [11]. Our patient failed to
show any such driver mutation on next generation sequencing. In
oncologic literature chemotherapeutic agents such as platinum based
(cisplatin) and microtubule assembly destabilizer (docetaxel) also have
been used with benefit to some extent however the prognosis of primary
lung SRCC remains poor [12].
3. Conclusion
Primary signet ring cell carcinoma of the lung is a rare tumor which
has been described to have very aggressive natural course and poor

Fig. 2. Pet scan showing right lung mass and adrenal gland metastasis.
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outcomes as compared to other tumors of the lungs. Its diagnosis needs a
thorough investigation to correctly differentiate a primary lung SRCC
from metastatic SRCC with the utilization of appropriate immunohis
tochemical staining, imaging studies and identifying gene mutations.
More data is required to assess the efficacy and survival benefits of
various treatment options.

[2] S.H. Ou, A. Ziogas, J.A. Zell, Primary signet-ring carcinoma (SRC) of the lung: a
population-based epidemiologic study of 262 cases with comparison to
adenocarcinoma of the lung, J. Thorac. Oncol. 5 (4) (2010) 420–427, https://doi.
org/10.1097/JTO.0b013e3181ce3b93.
[3] S.G. Wu, X.T. Chen, W.W. Zhang, et al., Survival in signet ring cell carcinoma
varies based on primary tumor location: a Surveillance, Epidemiology, and End
Results database analysis, Expet Rev. Gastroenterol. Hepatol. 12 (2) (2018)
209–214, https://doi.org/10.1080/17474124.2018.1416291.
[4] C.Y. Castro, C.A. Moran, D.G. Flieder, S. Suster, Primary signet ring cell
adenocarcinomas of the lung: a clinicopathological study of 15 cases,
Histopathology 39 (4) (2001) 397–401, https://doi.org/10.1046/j.13652559.2001.01224.x.
[5] J.M. Boland, J.A. Wampfler, J.S. Jang, et al., Pulmonary adenocarcinoma with
signet ring cell features: a comprehensive study from 3 distinct patient cohorts,
Am. J. Surg. Pathol. 38 (12) (2014) 1681–1688, https://doi.org/10.1097/
PAS.0000000000000280.
[6] T. Terada, Primary signet-ring cell carcinoma of the lung: a case report with an
immunohistochemical study, Int. J. Clin. Exp. Pathol. 5 (2) (2012) 171–174.
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